With Neurocrine Biosciences (NASDAQ:NBIX) these days, there's an element of "wait for it… wait for it… wait for it...," as the cat is largely out of the bag with respect to the efficacy and safety profile of the biotech's two lead drugs, but investors are still waiting for the new drug applications (or NDAs) to be filed with the FDA. At the same time, the company is probably in a window where most of the news updates on those programs are going to skew negative - there's just not all that much positive information left to come out at this point.
Still, these shares remain undervalued on the potential of those two lead drugs - elagolix and valbenazine. Competition, safety concerns, and cost will be relevant factors for both drugs, but both address significant under-served patient populations and I believe the revenue potential is significant.
Read the full article here:
Neurocrine Biosciences Building To A Big 2017